Article
The ELI-002 and Libtayo® combination will be studied in KRAS-driven tumors including Stage III and IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC) and unresectable, locally advanced or oligometastatic pancreatic ductal adenocarcinoma (PDAC) Excerpt from the Press Release: BOSTON, May 16, 2022 (GLOBE NEWSWIRE) — Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline…
Read More
–Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA®— –All three of NGM Bio’s wholly-owned myeloid reprogramming product candidates –NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, NGM831, an ILT3 antagonist antibody, and NGM438 – are now in the clinic–…
Read More
Therapeutic Solutions International Continues Parallel Development of COPD Program in Conjunction with Pivotal Clinical Trial in COVID-19 Excerpt from the Press Release: OCEANSIDE, Calif.–(BUSINESS WIRE)–Therapeutic Solutions International announced today new data demonstrating enhancement of therapeutic activities of the JadiCell™ through induction of a specific cell type called “Myeloid Derived Progenitor Cells”. In a series of…
Read More
New proof-of-concept approach offers faster, more accurate inferences about tumour populations. Excerpt from the Press Release: The prevalence of mutations in a tumour can provide clues about how the cancer has grown or evolved and how best to treat it. But making predictions about the evolution of mutated tumours using a single DNA sequenced biopsy…
Read More
Excerpt from the Press Release: The Ontario Brain Institute (OBI) has released a new set of clinical imaging modalities from a Province of Ontario Neurodevelopmental Network (POND) study for cohort of over 600 children and youth, some diagnosed with various neurodevelopmental disorders and others typically developing.This cleaned, standardized, and curated dataset is available for download on Brain-CODE, OBI’s neuroinformatics and analytics platform.…
Read More
ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate mechanisms contributing to its anti-tumor activity Non-gene-edited ADI-001 gamma delta CAR T cells demonstrated superior resilience to host versus graft targeting when compared to common gene-edited approaches Excerpt from the Press Release: MENLO PARK,…
Read More
SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain, and it contains no preservatives, surfactants, solvents, or particulates. The study met its primary endpoint with a highly statistically significant reduction in average daily leg pain in patients receiving SEMDEXATM compared to placebo (p<0.001).…
Read More
An analysis using the rank-preserving structural failure time model (RPSFTM), a method frequently employed in oncology to account for placebo crossover, estimated a 10.6-month longer median survival duration for AMX0035 participants Participants randomized to receive AMX0035 and who continued into the open-label extension (OLE) phase showed an 18.8-month longer median survival duration than participants who…
Read More
Research with renowned oncology expert Dr. Linda Carlson will assess feasibility of a virtual reality guided mindfulness program Excerpt from the Press Release: BOSTON, May 5, 2022 /PRNewswire/ — Rocket VR Health, a digital therapeutics company developing immersive therapy programs, is pleased to announce a new study in partnership with Dr. Linda Carlson, Enbridge Research Chair…
Read More
News Summary: Waters opens its newest innovation and research laboratory at University of Delaware (UD) Science, Technology and Advanced Research (STAR) campus Immerse™ Delaware brings together students, faculty, and Waters scientists with industry research partners to identify and address significant challenges facing the biopharmaceutical industry Lab opening milestone is part of multi-year Waters-UD research partnership…
Read More